All News
Will AI put me out of a job?
The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".
Read Article
ICYMI: Treatment of sclerosing skin disease:
-Progression: inflammation➡️sclerosis➡️ atrophy
-Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis
-First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks
Links:
Adela Castro AdelaCastro222 ( View Tweet)
@RichardPAConway on PMR
#RNL2025 @RheumNow
PMR mimics: look for mimics in unusual/refractory cases
- Suspect the mimics to avoid undertreatment or over-treatment
Conway: PMR is NOT easy. Easy to misdiagnosis, easy to mistreat. "One of our most challenging cases" https://t.co/WqPWwCuutF
Eric Dein ericdeinmd ( View Tweet)
Eric Dein @ericdeinmd
🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈 AI in RA? Can help with Rheum Boards Questions, though AI is not confident in answers May not be better than paper charts for triage Other roles: pt chatbot, AI scribe, research populations, generate DDx,… https://t.co/3vJ2gON6tR https://t.co/3ArtaRkhJp
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Recurrent Acute Oligoarthritis Recurrent Acute Oligoarthritis in a 40 yr. old man https://t.co/5D5qE05u1w https://t.co/tunU955MkH
Dr. John Cush RheumNow ( View Tweet)
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
https://t.co/MQtR3etpEH https://t.co/ZB4byi81on
Dr. John Cush RheumNow ( View Tweet)
Dr Cather treatment options in HS. The last 2 obviously in rheumatology's wheelhouse @RheumNow #RNL2025 https://t.co/vGfvQH05lv
Richard Conway RichardPAConway ( View Tweet)
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
Links:
Eric Dein ericdeinmd ( View Tweet)
The ‘dark’ side of
#Hidradenitis #suppurativa
👇
Smell of leaking lesions #HS
⬆️skin folds, buttock, axilla, also thighs, neck
⬆️depression
@RheumNow #RNL2025
‘ If pt doesn’t get in gown then not ready for systemic #Rx!’
Jennifer Clay
#ClinicalPearl https://t.co/tZzz5tielt
Links:
Janet Pope Janetbirdope ( View Tweet)
Pregnancy is 🔥 inflammatory
Hard to interpret MRI of SI joints in setting of pregnancy
Ideally, don't score MRI during pregnancy or 1 year afterwards, would be affected by the pregnancy
If needed for clinical eval, focus on structural lesions like erosions
#RNL2025 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway RichardPAConway ( View Tweet)
Pearls on Dermatomyositis:
-Negative myomarker does not r/o DM
-Pruritus can be a skin manifestation in DM🚨
-Combination therapy upfront =achieve faster remission
-Evidence for JAK inhibitors in management
-JAKis seem to have good effect in DM-calcinosis
-In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Importance of not over-relying on lab tests. We can test for what we can test for, but this is not comprehensive. For me in clinical practice - Postive antibodies can confirm diagnosis of DM but negative cannot exclude it. @RheumNow #RNL2025 https://t.co/Kyfzne4BSD
Richard Conway RichardPAConway ( View Tweet)
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx
Richard Conway RichardPAConway ( View Tweet)
Can treatment of PsO prevent PsA?
-Severity of PsO and obesity->Risk fx for PsA
-PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years
-Does ttx of PsO impact development of PsA?
Trials are mostly observational (several confounders)
TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Links:
Adela Castro AdelaCastro222 ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush RheumNow ( View Tweet)
Break a leg! Or a #hip
#AVN risk occurs even at 1 month of high / moderate dose #glucocorticoids
Shown by Michelle Petri @RheumNow #RNL2025
Risk in SLE is likely
👇
#disease #activity
And
#steroids
#SLE #systemic #lupus #erythematosus #steroids https://t.co/4EsQw9tY1u
Janet Pope Janetbirdope ( View Tweet)
Even a #SLE expert who wants all #lupus Pts on
No #chronic #prednisone
Realizes you can’t get everyone off #glucocorticoids
18% May be on chronic #steroids
But she keeps trying to taper
Michelle Petri
#RNL2025 @RheumNow https://t.co/SNP6Eep731
Janet Pope Janetbirdope ( View Tweet)
Predicting #PsA
PRESTO study #obvious risks are #predictive
Alexis R Ogdie @RheumNow #RNL2025
bad PsO 2X ^PsA
High BMI
Depression
Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5
Janet Pope Janetbirdope ( View Tweet)
Who’s liable for an incorrect #AI diagnosis or medical advice? @rheumnow #RNL2025 @RADoctor
TheDaoIndex KDAO2011 ( View Tweet)
